Eli Lilly and Company
General ticker "LLY" information:
- Sector: Health Care
- Industry: Drug Manufacturers - General
- Capitalization: $892.9B (TTM average)
Eli Lilly and Company follows the US Stock Market performance with the rate: 41.3%.
Estimated limits based on current volatility of 1.8%: low 1218.36$, high 1262.01$
Factors to consider:
- Earnings expected soon, date: 2026-10-29 bmo
- Company included in S&P500 list
- Company pays dividends (quarterly): last record date 2026-08-14, amount 1.73$ (Y0.55%)
- Total employees count: 50000 (+6.4%) as of 2025
- US accounted for 19.9% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: R&D failure, Regulatory and compliance, Pricing pressure, IP loss, Supply chain disruptions
- Current price 12.5% above estimated high
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [787.17$, 1117.08$]
- 2026-12-31 to 2027-12-31 estimated range: [863.00$, 1208.57$]
Financial Metrics affecting the LLY estimates:
- Negative: with PPE of 44.5 at the end of fiscal year the price was high
- Negative: Operating cash flow per share per price, % of 1.74 <= 2.37
- Positive: Operating profit margin, % of 40.35 > 33.79
- Positive: -1.23 < Investing cash flow per share per price, % of -1.13
- Positive: 14.78 < Industry operating profit margin (median), % of 24.67
- Positive: Interest expense per share per price, % of 0 <= 0
- Positive: 5.56 < Industry operating cash flow per share per price (median), % of 5.61
- Positive: Return on assets ratio (scaled to [-100,100]) of 15.51 > 10.70
Short-term LLY quotes
Relationship graph
Long-term LLY plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $34,124.10MM | $45,042.70MM | $65,179.00MM |
| Operating Expenses | $27,569.50MM | $27,541.00MM | $38,877.00MM |
| Operating Income | $6,554.60MM | $17,501.70MM | $26,302.00MM |
| Non-Operating Income | $0.00MM | $-4,821.30MM | $-571.00MM |
| R&D Expense | $9,313.00MM | $10,991.00MM | $13,337.00MM |
| Income(Loss) | $6,554.60MM | $12,680.40MM | $25,731.00MM |
| Taxes | $1,314.20MM | $2,090.40MM | $5,091.00MM |
| Net Income(Loss)* | $5,240.40MM | $10,590.00MM | $20,640.00MM |
| Stockholders Equity | $10,771.90MM | $14,192.10MM | $26,535.00MM |
| Inventory | $5,772.80MM | $7,589.20MM | $13,744.00MM |
| Assets | $64,006.30MM | $78,714.90MM | $112,476.00MM |
| Operating Cash Flow | $4,240.00MM | $8,818.00MM | $16,813.00MM |
| Capital expenditure | $7,392.10MM | $5,058.00MM | $7,841.00MM |
| Investing Cash Flow | $-7,153.00MM | $-9,302.00MM | $-10,972.00MM |
| Financing Cash Flow | $3,496.00MM | $1,230.00MM | $-2,213.00MM |
| Earnings Per Share** | $5.83 | $11.76 | $22.98 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.